Debra L Pittman

US Patent:

6902735, Jun 7, 2005

Filed:

Mar 19, 2002

Appl. No.:

10/102080

Inventors:

Kenneth Jacobs - Newton MA, US
Kerry Kelleher - Marlborough MA, US
McKeough Carlin - Cambridge MA, US
Samuel Goldman - Acton MA, US
Debra Pittman - Windham NH, US
Sha Mi - Belmont MA, US
Steven Neben - Acton MA, US
Joanne Giannotti - Acton MA, US
Margaret M. Golden-Fleet - Medford MA, US

Assignee:

Genetics Institute, LLC - Cambridge MA

International Classification:

A61K039/395

US Classification:

4241451, 4241581, 4241931, 53038823, 5303892

Abstract:

Polynucleotides encoding human CTLA-8 (now known as IL-17F) and related proteins are disclosed. Human CTLA-8 and related proteins, including anti-human IL-17F antibodies, and methods for their production are also disclosed. Methods of treatment using human CTLA-8 proteins, rat CTLA-8 proteins and herpes CTLA-8 proteins are also provided.

US Patent:

6939545, Sep 6, 2005

Filed:

Feb 25, 2002

Appl. No.:

10/084298

Inventors:

Kenneth Jacobs - Newton MA, US
Debra D. Pittman - Windham NH, US
Lynette Fouser - Acton MA, US
Vikki Spaulding - Lowell MA, US
Dejun Xuan - Chestnut Hill MA, US

Assignee:

Genetics Institute, LLC - Cambridge MA

International Classification:

A61K039/395
A61K039/00
C07K016/00
C07K014/555
C07K016/24

US Classification:

4241581, 424 852, 4241451, 4241981, 530350

Abstract:

Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.

US Patent:

7279559, Oct 9, 2007

Filed:

Sep 27, 2002

Appl. No.:

10/256977

Inventors:

Kenneth Jacobs - Newton MA, US
Debra D. Pittman - Windham NH, US
Lynette Fouser - Acton MA, US
Vikki Spaulding - Lowell MA, US
Dejun Xuan - Chestnut Hill MA, US

Assignee:

Genetics Institute, LLC - Cambridge MA

International Classification:

C07K 16/00
C12P 21/08

US Classification:

5303871, 5303873, 53038815, 53038823, 5303913

Abstract:

Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.

US Patent:

7638604, Dec 29, 2009

Filed:

Jun 22, 2004

Appl. No.:

10/873972

Inventors:

Jing Li - Lexington MA, US
Xiang-Yang Tan - Reading MA, US
Kathleen N. Tomkinson - Cambridge MA, US
Debra D. Pittman - Windham NH, US
Geertruida M. Veldman - Sudbury MA, US
Lynette Fouser - Acton MA, US

Assignee:

Genetics Institute, LLC - Cambridge MA

International Classification:

C12P 21/08
A61K 39/395

US Classification:

5303881, 4241451, 435 7021

Abstract:

Antibodies and antigen-binding fragments thereof that bind interleukin-22 (IL-22), in particular, human IL-22, and their uses in regulating IL-22-associated immune responses are disclosed. The antibodies disclosed herein are useful in diagnosing, preventing, or treating IL-22-associated immune disorders, e. g. , autoimmune disorders (e. g. , arthritis).

US Patent:

7951372, May 31, 2011

Filed:

Aug 31, 2007

Appl. No.:

11/896363

Inventors:

Kenneth Jacobs - Newton MA, US
Debra D. Pittman - Windham NH, US
Lynette Fouser - Acton MA, US
Vikki Spaulding - Lowell MA, US
Dejun Xuan - Chestnut Hill MA, US

Assignee:

Wyeth LLC - Madison NJ

International Classification:

A61K 39/395
A61K 39/00

US Classification:

4241391, 4241301, 4241331, 4241351, 4241411, 4241421, 4241451

Abstract:

Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.

US Patent:

20050214315, Sep 29, 2005

Filed:

Jan 14, 2005

Appl. No.:

11/034843

Inventors:

Kenneth Jacobs - Newton MA, US
Kerry Kelleher - Marlborough MA, US
McKeough Carlin - Cambridge MA, US
Samuel Goldman - Acton MA, US
Debra Pittman - Windham NH, US
Sha Mi - Belmont MA, US
Steven Neben - Acton MA, US
Joanne Giannotti - Acton MA, US
Margaret Golden-Fleet - Medford MA, US

Assignee:

GENETICS INSTITUTE, LLC - CAMBRIDGE MA

International Classification:

A61K039/395
C07H021/04
C07K014/74

US Classification:

424185100, 435069100, 435320100, 435325000, 530350000, 536023500

Abstract:

Polynucleotides encoding human CTLA-8 (now known as IL-17F) and related proteins are disclosed. Human CTLA-8 and related proteins, including anti-human IL-17F antibodies, and methods for their production are also disclosed. Methods of treatment using human CTLA-8 and related proteins, rat CTLA-8 proteins and herpes CTLA-8 proteins are also provided.

US Patent:

20050238648, Oct 27, 2005

Filed:

Jun 20, 2005

Appl. No.:

11/157387

Inventors:

Kenneth Jacobs - Newton MA, US
Debra Pittman - Windham NH, US
Lynette Fouser - Acton MA, US
Vikki Spaulding - Lowell MA, US
Dejun Xuan - Chestnut Hill MA, US

International Classification:

A61K039/395
C07K016/24

US Classification:

424145100, 530388230

Abstract:

Inhibitors of IL-22 are disclosed as well as pharmaceutical compositions and methods of using same. The inhibitors include IL-22 antibodies and are useful for treating inflammatory disorders.

US Patent:

20070274987, Nov 29, 2007

Filed:

May 25, 2007

Appl. No.:

11/806000

Inventors:

Valerie Clerin - Watertown MA, US
Heather Shih - Andover MA, US
Kathleen Shields - Harvard MA, US
Jeffrey Feldman - Arlington MA, US
Gustave Hebert - Arlington MA, US
Debra Pittman - Windham NH, US
Nanhua Deng - Brookline MA, US

International Classification:

A61K 39/395
A61K 38/17
C07H 21/04
A61K 39/00
C07K 14/705
C07K 16/28

US Classification:

424133100, 435069100, 435320100, 435325000, 530395000, 514008000, 536023500, 530388220

Abstract:

The present invention provides isolated and purified polynucleotides, polypeptides, and antibodies related to mammalian (e.g., mouse and human) legumain and the novel legumain splice variant, ZB-1. The invention further relates to the use of these isolated and purified polynucleotides, polypeptides, and antibodies, as well as other legumain and ZB-1 agonists and antagonists, in modulating legumain and/or ZB-1 activity, expression, and/or secretion in a cell or cell population, e.g., monocytes, macrophages, foam cells, vascular endothelial cells, kidney proximal tubule cells, arterial endothelial cells, sites of inflammatory cell invasion into a vessel intima, and neointimal lesional areas of an artery. The invention also provides legumain and ZB-1 antagonists, e.g., antagonistic small molecules, antibodies and antibody fragments to legumain and ZB-1, legumain and ZB-1 inhibitory polypeptides, and legumain and ZB-1 inhibitory polynucleotides. The present invention is also directed to novel methods for diagnosing, prognosing, monitoring, treating, ameliorating and/or preventing vascular disorders/diseases and inflammatory disorders/diseases.